prehybridization buffer (1% SDS, 2 X SSC, 10% dextran sulphate, 50% deionized formamide) for 4 h at 42°C.

Please cancel the present "SEQUENCE LISTING," pages 35-38, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 4, at the end of the application. Cancel the page numbers of the Claims and Abstract and renumber as pages 35-38, accordingly.

REMARKS

Applicants assert that this amendment is a duplicate submission of a similar Statement to Use the Sequence Listing CRF from the Parent Application and Preliminary Amendment submitted October 17, 2001 in response to a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825 mailed April 20, 2001. Enclosed are copies of all documents submitted at that time. Applicants have not received a return postcard as receipt that the documents submitted were received by the USPTO.

Applicants have contacted Ms. Stokes of the Customer Service Center, Initial Patent Examination Division by telephone with regard to the Notice of Incomplete Reply mailed December 26, 2001, accompanied by the Attachment to Notice of Incomplete Reply, a copy of which is enclosed. Applicants were assured that resubmission of these documents would comply with the request to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures in the original Notice to File Missing Parts of Nonprovisional Application mailed April 20, 2001, and the restated request in the Notice of Incomplete Reply mailed December 26, 2001.

The Attachment to Notice of Incomplete Reply states that "Sequences were found at page(s) 18, 27, 35-38, and/or Figure 1." The application as filed contains

reference to SEQ ID NO:1 on page 6, line 6; page 8, lines 12 and 19; page 10, line 17; and page 18, line 18 of the Specification, and in pending claim 10, line 2. The actual sequence for SEQ ID NO:1 appears in the "SEQUENCE LISTING" submitted with the application, pages 35-38, and was replaced by the Substitute Sequence Listing filed in Application No. 09/072,914, filed July 14, 2000. The identical SEQ ID NO:1 also appears in Figure 1.

Reference to a SEQ ID NO:5 appears on page 27, lines 21-22, but has been deleted by this amendment, since no SEQ ID NO:5 was disclosed in either this application or the parent application.

This amendment has been sent to the Arlington, VA address in compliance with instructions received in an "Attachment to "Notice to Comply with Requirements...Sequence Disclosures", Rev. 12/27/2001, received in other correspondence with the USPTO, and confirmed by telephone discussions with Division Chief Arti Shah and Mr. Mark Spencer of the Arlington Office.

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a paper copy of the required Sequence Listing containing the above named sequence, SEQ ID NO:1, which is identical to that contained on the the floppy disk CRF submitted July 14, 2000.

The information contained in the computer readable form of Application No. 09/072,914 was prepared through the use of the software program "PatentIn" and was identical to that of the paper copy. This amendment contains no new matter.

Attached hereto is a marked-up version of the changes made to the Specification by the current Amendment. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Kevin L. Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
KLB:dmw

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 20 of page 27 has been amended as follows:

Sequence analysis of the PCR amplified product (Example IV) shows perfect coincidence with the C-terminal amino acid sequence of peptide 1~~(SEQ. ID No.5)~~. Using the 450 bp DNA fragment as hybridization probe, a human placenta cDNA gene library (Clontech) was screened. To that end, E.coli strain Y1090 host cells were incubated overnight with vigorous shaking at 37˚C in LB medium (per liter: 10 g tryptone, 5 g yeast extract, 10 g NaCI) containing 0.2% maltose and 10mM MgSP. For each culture plate, 0.3 ml of host cell culture was mixed with 3 x10^4 3 x 10^4 pfu phage and incubated for 20 min at 37˚C. The mixtures of host cells and phage were added to 8 ml of LB-medium containing 0.7% agarose (LB-top-agarose) that were pre-warmed at 48˚C and poured onto 20 agar plates (135 x 15 mm). Plaques were visible after incubation for 6 to 8 h at 37˚C and plates were chilled to 4˚C for 1 h. Plaques were transferred to Colony/Plaque Screen nylon transfer membranes (NEN Research Products, Dupont Boston, MA) for 3 min, followed by denaturation (2 times in 0.5 N NaOH for 2 min)< renaturation (2 times in 1.0 M Tris-HCl, pH7.5 for 2 min) and fixation by air drying. Prehybridization of 20 membranes was carried out in two plastic bags containing 10 membranes each, using 20 ml of prehybridization buffer (1% SDS, 2 X SSC, 10% dextran sulphate, 50% deionized formamide) for 4 h at 42˚C.